According to the 2020 European Association of Neuro-Oncology (EANO) guidelines, PCV is the standard of care for IDH-mutant and 1p/19q codeleted oligodendroglioma WHO grade II and grade III, and for IDH-mutant astrocytomas WHO grade II [61,91]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).